Exploring the ocean for new drug developments: Marine pharmacology

Journal of Pharmacy and Bioallied Sciences

Volumn 8, Issue 2, 2016, Pages 83-91

  Malve, Harshad ^a  

^a Lead Medical   (India)

Author keywords

Anticancer; bryostatin; cytarabine; keyhole limpet hemocyanin; mariculture; sponge; ziconotide

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; BRYOSTATIN 1; CYTARABINE; DEHYDRODIDEMNIN B; ELISIDEPSIN; ENFORTUMABVEDOTIN; ERIBULIN; HALICHONDRIN B; HEMIASTERLIN; NATURAL PRODUCT; NEW DRUG; OMEGA CONOTOXIN CVID; OMEGA CONOTOXIN MVIIA; PLINABULIN; PSEUDOPTEROSIN DERIVATIVE; SALINOSPORAMIDE A; SOBLIDOTIN; TASIDOTIN; TETRODOTOXIN; TRABECTEDIN; UNCLASSIFIED DRUG; VIDARABINE; VORSETUZUMAB MAFODOTIN; ZALYPSIS;

ANALGESIC ACTIVITY; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIMALARIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG MANUFACTURE; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; IMMUNOMODULATION; INDIA; MARINE ENVIRONMENT; MARINE SPECIES; NEUROPROTECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW;

EID: 84962428164     PISSN: None     EISSN: 09757406     Source Type: Journal    
DOI: 10.4103/0975-7406.171700     Document Type: Review

References (39)

1. Kijjoa A, Sawangwong P. Drugs and cosmetics from the sea. Mar Drugs 2004;2:73-82.
2. Mayer AM, Glaser KB, Cuevas C, Jacobs RS, Kem W, Little RD, et al. The odyssey of marine pharmaceuticals: A current pipeline perspective. Trends Pharmacol Sci 2010;31:255-65.
3. Vignesh S, Raja A, James RA. Marine drugs: Implication and future studies. Int J Pharmacol 2011;7:22-30.
4. Martins A, Vieira H, Gaspar H, Santos S. Marketed marine natural products in the pharmaceutical and cosmeceutical industries: Tips for success. Mar Drugs 2014;12:1066-101.
5. Cragg GM, Grothaus PG, Newman DJ. Impact of natural products on developing new anti-cancer agents. Chem Rev 2009;109:3012-43.
6. Margulis L, Schwartz KV. Five Kingdoms-An Illustrated Guide to the Phyla of Life on Earth. 3rd ed. New York, USA: W.H. Freeman and Company; 1998.
7. Donia M, Hamann MT. Marine natural products and their potential applications as anti-infective agents. Lancet Infect Dis 2003;3:338-48.
8. Bergmann W, Stempien MF. Contributions to the study of marine products. XLIII. The nucleosides of sponges. V. The synthesis of spongosine. J Org Chem 1957;2:1557-75.
9. Murti Y, Agarwal T. Marine derived pharmaceuticals-development of natural health products from marine biodiversity. Int J ChemTech Res 2010;2:2198-217.
10. Imhoff JF, Labes A, Wiese J. Bio-mining the microbial treasures of the ocean: New natural products. Biotechnol Adv 2011;29:468-82.
11. Anand TP, Bhat AW, Shouche YS, Roy U, Siddharth J, Sarma SP. Antimicrobial activity of marine bacteria associated with sponges from the waters off the coast of South East India. Microbiol Res 2006;161:252-62.
12. Thakur NL, Thakur AN, Muller WEG. Marine natural products in drug discovery. Natural Product Radiance 2005;4:471-7.
13. Desbois AP, Mearns-Spragg A, Smith VJ. A fatty acid from the diatom Phaeodactylum tricornutum is antibacterial against diverse bacteria including multi-resistant Staphylococcus aureus (MRSA). Mar Biotechnol (NY) 2009;11:45-52.
14. Dellai A, Laroche-Clary A, Mhadhebi L, Robert J, Bouraoui A. Anti-inflammatory and antiproliferative activities of crude extract and its fractions of the defensive secretion from the mediterranean sponge. Spongia officinalis. Drug Dev Res 2010;71:412-8.
15. Suganthy N, Karutha Pandian S, Pandima Devi K. Neuroprotective effect of seaweeds inhabiting South Indian coastal area (Hare Island, Gulf of Mannar Marine Biosphere Reserve): Cholinesterase inhibitory effect of Hypnea valentiae and Ulva reticulata. Neurosci Lett 2010;468:216-9.
16. Ben Kahla-Nakbi A, Haouas N, El Ouaer A, Guerbej H, Ben Mustapha K, Babba H. Screening of antileishmanial activity from marine sponge extracts collected off the Tunisian coast. Parasitol Res 2010;106:1281-6.
17. Rashid ZM, Lahaye E, Defer D, Douzenel P, Perrin B, Bourgougnon N, et al. Isolation of a sulphated polysaccharide from a recently discovered sponge species (Celtodoryx girardae) and determination of its anti-herpetic activity. Int J Biol Macromol 2009;44:286-93.
18. Bringmann G, Gulder TA, Lang G, Schmitt S, Stöhr R, Wiese J, et al. Large-scale biotechnological production of the antileukemic marine natural product sorbicillactone A. Mar Drugs 2007;5:23-30.
19. Harris JR, Markl J. Keyhole limpet hemocyanin (KLH): A biomedical review. Micron 1999;30:597-623.
20. Curtis JE, Hersh EM, Butler WT, Rossen RD. Antigen dose in the human immune response. Dose-relationships in the human immune response to Keyhole limpet hemocyanin. J Lab Clin Med 1971;78:61-9.
21. Wirguin I, Suturkova-Milosevic L, Briani C, Latov N. Keyhole limpet hemocyanin contains Gal(beta 1-3)-GalNAc determinants that are cross-reactive with the T antigen. Cancer Immunol Immunother 1995;40:307-10.
22. Skov MJ, Beck JC, de Kater AW, Shopp GM. Nonclinical safety of ziconotide: An intrathecal analgesic of a new pharmaceutical class. Int J Toxicol 2007;26:411-21.
23. Miyaoka H, Shimomura M, Kimura H, Yamada Y, Kim HS, Yusuke W. Antimalarial activity of kalihinol A and new relative diterpenoids from the Okinawan sponge, Acanthella sp. Tetrahedron 1998;54:13467-74.
24. Moczydlowski EG. The molecular mystique of tetrodotoxin. Toxicon 2013;63:165-83.
25. Chau R, Kalaitzis JA, Neilan BA. On the origins and biosynthesis of tetrodotoxin. Aquat Toxicol 2011;104:61-72.
26. Kanoh K, Kohno S, Katada J, Hayashi Y, Muramatsu M, Uno I. Antitumor activity of phenylahistin in vitro and in vivo. Biosci Biotechnol Biochem 1999;63:1130-3.
27. Jayamanne A, Jeong HJ, Schroeder CI, Lewis RJ, Christie MJ, Vaughan CW. Spinal actions of omega-conotoxins, CVID, MVIIA and related peptides in a rat neuropathic pain model. Br J Pharmacol 2013;170:245-54.
28. Daly NL, Craik DJ. Conopeptides as novel options for pain management. Drugs Future 2011;36:25-32.
29. Yanagita Y, Takenaka T. Astellas' drug discovery strategy: Focus on oncology. Jpn J Clin Oncol 2012;42:241-6.
30. Iyer U, Kadambi VJ. Antibody drug conjugates-Trojan horses in the war on cancer. J Pharmacol Toxicol Methods 2011;64:207-12.
31. Newman DJ, Cragg GM. Marine-sourced anti-cancer and cancer pain control agents in clinical and late preclinical development. Mar Drugs 2014;12:255-78.
32. Mayer AM, Rodríguez AD, Taglialatela-Scafati O, Fusetani N. Marine pharmacology in 2009-2011: Marine compounds with antibacterial, antidiabetic, antifungal, anti-inflammatory, antiprotozoal, antituberculosis, and antiviral activities; affecting the immune and nervous systems, and other miscellaneous mechanisms of action. Mar Drugs 2013;11:2510-73.
33. Bhatnagar I, Kim SK. Marine antitumor drugs: Status, shortfalls and strategies. Mar Drugs 2010;8:2702-20.
34. Sawadogo WR, Schumacher M, Teiten MH, Cerella C, Dicato M, Diederich M. A survey of marine natural compounds and their derivatives with anti-cancer activity reported in 2011. Molecules 2013;18:3641-73.
35. Molinski TF, Dalisay DS, Lievens SL, Saludes JP. Drug development from marine natural products. Nat Rev Drug Discov 2009;8:69-85.
36. Radjasa OK, Vaske YM, Navarro G, Vervoort HC, Tenney K, Linington RG, et al. Highlights of marine invertebrate-derived biosynthetic products: Their biomedical potential and possible production by microbial associants. Bioorg Med Chem 2011;19:6658-74.
37. Maier ME. Structural revisions of natural products by total synthesis. Nat Prod Rep 2009;26:1105-24.
38. Gerwick WH, Moore BS. Lessons from the past and charting the future of marine natural products drug discovery and chemical biology. Chem Biol 2012;19:85-98.
39. Gerwick WH, Fenner AM. Drug discovery from marine microbes. Microb Ecol 2013;65:800-6.